Association of Cardiovascular Biomarkers With Cardiac Allograft Vasculopathy and Atherosclerotic Coronary Artery Disease

IF 1.9 4区医学 Q2 SURGERY

Clinical Transplantation Pub Date : 2025-06-09 DOI:10.1111/ctr.70195

Lukas Köster, Jessica Weimann, Alexander Bernhard, Benjamin Bay, Christopher M. Blaum, Thiess Lorenz, Tanja Zeller, Christoph Waldeyer, Hermann Reichenspurner, Paulus Kirchhof, Stefan Blankenberg, Christina Magnussen, Fabian J. Brunner

{"title":"Association of Cardiovascular Biomarkers With Cardiac Allograft Vasculopathy and Atherosclerotic Coronary Artery Disease","authors":"Lukas Köster, Jessica Weimann, Alexander Bernhard, Benjamin Bay, Christopher M. Blaum, Thiess Lorenz, Tanja Zeller, Christoph Waldeyer, Hermann Reichenspurner, Paulus Kirchhof, Stefan Blankenberg, Christina Magnussen, Fabian J. Brunner","doi":"10.1111/ctr.70195","DOIUrl":null,"url":null,"abstract":"Background: Cardiac allograft vasculopathy (CAV) remains a barrier to long-term survival after heart transplantation. Little is known about cardiovascular biomarkers in CAV and how they compare to biomarkers in atherosclerotic coronary artery disease (CAD).Purpose: This study addresses these gaps by investigating the associations of high-sensitivity troponin I and T (hsTnI/T), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) with CAV and CAD.Methods: Posttransplant patients undergoing angiography were matched 1:2 with nontransplant patients by age, sex, hypertension, BMI and angiographic severity of CAV and CAD. Disease severity was classified using the International Society for Heart and Lung Transplantation.Results: Sixty-three transplant and 126 matched nontransplant patients (median age 55.9 years, 5.8 years posttransplant, 8.5% female) were analyzed. Among transplant patients, 17.5% had mild, 7.9% moderate, 7.9% severe, and 66.7% no CAV. HsTnI/T (OR per SD = 2.21/2.38, CI = 1.17–4.66/1.21–5.69, p = 0.022/0.026) and NT-proBNP (OR per SD = 2.86, 95% CI 1.50–6.39, p = 0.004) were significantly associated with CAV. While hsTnT (OR per SD = 1.60, 95% CI 1.06–2.52, p = 0.030) and hsCRP (OR per SD = 1.61, 95% CI 1.08–2.47, p = 0.023) were significantly associated with CAD.Conclusion: Distinct biomarker profiles were observed: HsTnI, hsTnT, and NT-proBNP showed associations with CAV, while hsTnT and hsCRP were associated with CAD.","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70195","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70195","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cardiac allograft vasculopathy (CAV) remains a barrier to long-term survival after heart transplantation. Little is known about cardiovascular biomarkers in CAV and how they compare to biomarkers in atherosclerotic coronary artery disease (CAD).

Purpose: This study addresses these gaps by investigating the associations of high-sensitivity troponin I and T (hsTnI/T), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) with CAV and CAD.

Methods: Posttransplant patients undergoing angiography were matched 1:2 with nontransplant patients by age, sex, hypertension, BMI and angiographic severity of CAV and CAD. Disease severity was classified using the International Society for Heart and Lung Transplantation.

Results: Sixty-three transplant and 126 matched nontransplant patients (median age 55.9 years, 5.8 years posttransplant, 8.5% female) were analyzed. Among transplant patients, 17.5% had mild, 7.9% moderate, 7.9% severe, and 66.7% no CAV. HsTnI/T (OR per SD = 2.21/2.38, CI = 1.17–4.66/1.21–5.69, p = 0.022/0.026) and NT-proBNP (OR per SD = 2.86, 95% CI 1.50–6.39, p = 0.004) were significantly associated with CAV. While hsTnT (OR per SD = 1.60, 95% CI 1.06–2.52, p = 0.030) and hsCRP (OR per SD = 1.61, 95% CI 1.08–2.47, p = 0.023) were significantly associated with CAD.

Conclusion: Distinct biomarker profiles were observed: HsTnI, hsTnT, and NT-proBNP showed associations with CAV, while hsTnT and hsCRP were associated with CAD.

查看原文本刊更多论文

心血管生物标志物与心脏异体移植血管病变和动脉粥样硬化性冠状动脉疾病的关系

背景：同种异体心脏移植血管病变（CAV）仍然是心脏移植术后长期生存的障碍。关于CAV的心血管生物标志物以及它们如何与动脉粥样硬化性冠状动脉疾病（CAD）的生物标志物进行比较，我们知之甚少。目的：本研究通过研究高敏感性肌钙蛋白I和T （hsTnI/T）、n端前b型利钠肽（NT-proBNP）和高敏感性c反应蛋白（hsCRP）与CAV和CAD的关系来解决这些空白。方法：移植后行血管造影的患者按年龄、性别、高血压、BMI、CAV和CAD血管造影严重程度与非移植患者1:2配对。疾病严重程度根据国际心肺移植学会进行分类。结果：分析了63例移植患者和126例匹配的非移植患者（中位年龄55.9岁，移植后5.8年，8.5%为女性）。在移植患者中，17.5%为轻度，7.9%为中度，7.9%为重度，66.7%为无CAV。HsTnI/T （OR / SD = 2.21/2.38, CI = 1.17-4.66/1.21-5.69, p = 0.022/0.026）和NT-proBNP （OR / SD = 2.86, 95% CI 1.50-6.39, p = 0.004）与CAV显著相关。而hsTnT （OR / SD = 1.60, 95% CI 1.06-2.52, p = 0.030）和hsCRP （OR / SD = 1.61, 95% CI 1.08-2.47, p = 0.023）与CAD显著相关。结论：观察到不同的生物标志物谱：HsTnI、hsTnT和NT-proBNP与CAV相关，而hsTnT和hsCRP与CAD相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Transplantation 医学-外科

CiteScore

3.70

自引率

4.80%

发文量

286

审稿时长

2 months

期刊介绍： Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.